EXEL — Exelixis Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapHigh Flyer

Annual income statement for Exelixis, fiscal year end - January 3rd, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 30th	2023 December 29th	2025 January 3rd
Period Length:	52 W	52 W	52 W	52 W	53 W
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	988	1,435	1,611	1,830	2,169
Cost of Revenue
Gross Profit	951	1,382	1,553	1,758	2,092
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Total Operating Expenses	877	1,148	1,410	1,659	1,564
Operating Profit	110	287	201	171	605
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	131	294	234	258	682
Provision for Income Taxes
Net Income After Taxes	112	231	182	208	521
Net Income Before Extraordinary Items
Net Income	112	231	182	208	521
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	112	231	182	208	521
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.352	0.717	0.562	0.646	1.98